RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment
- Written by PR Newswire
![]() |
YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced that its independently developed mesothelin-targeting antibody-drug conjugate (ADC), RC88, has recently received Investigational New Drug (IND) approval from the U.S. Food and...















